Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

Achievement of all anticipated 2024 milestones and accelerated development timelines reinforce progress on OnTarget 2026 operating plan towards first approved product in 2026Leading medical oncologist Alice Shaw, M.D., Ph.D. appointed to Scientific Advisory BoardStrong cash position of $1.2 billion, including proceeds from upsized$575 million public offering, expected to extend operating runway into 2028CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharm ...